K
Karin Avila
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 8
Citations - 1112
Karin Avila is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Chemoradiotherapy & Total mesorectal excision. The author has an hindex of 6, co-authored 8 publications receiving 861 citations. Previous affiliations of Karin Avila include Kettering University.
Papers
More filters
Journal ArticleDOI
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
Julio Garcia-Aguilar,Oliver S. Chow,David D. Smith,Jorge E. Marcet,Peter A. Cataldo,Madhulika G. Varma,Anjali S. Kumar,Samuel Oommen,Theodore Coutsoftides,Steven R. Hunt,Michael J. Stamos,Charles A. Ternent,Daniel O. Herzig,Alessandro Fichera,Blase N. Polite,David W. Dietz,Sujata Patil,Karin Avila +17 more
TL;DR: Delivery of mFOLFOX6 after chemoradiation and before total mesorectal excision has the potential to increase the proportion of patients eligible for less invasive treatment strategies; this strategy is being tested in phase 3 clinical trials.
Journal ArticleDOI
Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.
Julio Garcia-Aguilar,David D. Smith,Karin Avila,Emily K. Bergsland,Peiguo Chu,Richard M. Krieg +5 more
TL;DR: Intense neoadjuvant therapy consisting of CRT followed by additional chemotherapy (mFOLFOX-6), and delaying surgery may result in a modest increase in pCR rate without increasing complications in patients undergoing TME for locally advanced rectal cancer.
Journal ArticleDOI
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management
J. Joshua Smith,Oliver S. Chow,Marc J. Gollub,Garrett M. Nash,Larissa K. Temple,Martin R. Weiser,Jose G. Guillem,Philip B. Paty,Karin Avila,Julio Garcia-Aguilar +9 more
TL;DR: This study compares 3-year disease-free survival (DFS) in an entire population of patients with LARC, including those with cCR and those with pCR, and is the first NOM trial utilizing a regression schema for response assessment in a prospective fashion.
Journal ArticleDOI
KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Oliver S. Chow,Deborah Kuk,Metin Keskin,J. Joshua Smith,Niedzica Camacho,Raphael Pelossof,Chin-Tung Chen,Zhenbin Chen,Karin Avila,Martin R. Weiser,Michael F. Berger,Sujata Patil,Emily K. Bergsland,Julio Garcia-Aguilar +13 more
TL;DR: KRAS mutation is independently associated with a lower pCR rate in locally advanced rectal cancer after adjusting for variations in neoadjuvant regimen andGenomic data can potentially be used to select patients for “watch and wait” strategies.
Journal ArticleDOI
Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME.
Julio Garcia-Aguilar,Jorge E. Marcet,T. Coutsoftides,Peter A. Cataldo,Alessandro Fichera,L. E. Smith,Samuel Oommen,Steven R. Hunt,Daniel O. Herzig,David W. Dietz,Madhulika G. Varma,Charles A. Ternent,Michael J. Stamos,Karin Avila,David D. Smith +14 more
TL;DR: Advanced rectal cancer patients who receive pre-operative CRT and increasing cycles of chemotherapy before surgery have a higher pCR rate without increasing AEs or surgical complications.